CN1985994B - 改进的包含霉酚酸盐的包有肠溶衣的药物组合物 - Google Patents
改进的包含霉酚酸盐的包有肠溶衣的药物组合物 Download PDFInfo
- Publication number
- CN1985994B CN1985994B CN2005100482039A CN200510048203A CN1985994B CN 1985994 B CN1985994 B CN 1985994B CN 2005100482039 A CN2005100482039 A CN 2005100482039A CN 200510048203 A CN200510048203 A CN 200510048203A CN 1985994 B CN1985994 B CN 1985994B
- Authority
- CN
- China
- Prior art keywords
- mycophenolate
- sodium
- dosage
- mycophenolate sodium
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 title abstract description 147
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 title abstract description 66
- 229940014456 mycophenolate Drugs 0.000 title abstract description 51
- 239000003814 drug Substances 0.000 title abstract description 33
- 239000000203 mixture Substances 0.000 title abstract description 10
- 229960000951 mycophenolic acid Drugs 0.000 claims abstract description 82
- 239000002702 enteric coating Substances 0.000 claims abstract description 17
- 238000009505 enteric coating Methods 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- FHQMKMYTNSVUAT-UHFFFAOYSA-N dioctyl benzene-1,2-dicarboxylate ethenyl acetate Chemical compound C(C=1C(C(=O)OCCCCCCCC)=CC=CC1)(=O)OCCCCCCCC.C(C)(=O)OC=C FHQMKMYTNSVUAT-UHFFFAOYSA-N 0.000 claims description 5
- 229920006389 polyphenyl polymer Polymers 0.000 claims description 5
- DOZYTHNHLLSNIK-JOKMOOFLSA-M mycophenolate sodium Chemical compound [Na+].OC1=C(C\C=C(/C)CCC([O-])=O)C(OC)=C(C)C2=C1C(=O)OC2 DOZYTHNHLLSNIK-JOKMOOFLSA-M 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract description 2
- WWMQIJFJSHVMDM-UHFFFAOYSA-N 2-ethenoxycarbonylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)OC=C WWMQIJFJSHVMDM-UHFFFAOYSA-N 0.000 abstract 1
- 230000003578 releasing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 28
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 20
- 229930105110 Cyclosporin A Natural products 0.000 description 19
- 241000282472 Canis lupus familiaris Species 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 206010012735 Diarrhoea Diseases 0.000 description 16
- 239000011248 coating agent Substances 0.000 description 16
- 238000000576 coating method Methods 0.000 description 16
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 16
- 238000011160 research Methods 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 239000002775 capsule Substances 0.000 description 15
- 239000000890 drug combination Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 229960003444 immunosuppressant agent Drugs 0.000 description 10
- 230000001861 immunosuppressant effect Effects 0.000 description 10
- 239000003018 immunosuppressive agent Substances 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 206010003694 Atrophy Diseases 0.000 description 7
- 101710088194 Dehydrogenase Proteins 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 230000037444 atrophy Effects 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- 238000004820 blood count Methods 0.000 description 5
- 206010061428 decreased appetite Diseases 0.000 description 5
- 210000001630 jejunum Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 231100000025 genetic toxicology Toxicity 0.000 description 4
- 230000001738 genotoxic effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- -1 alkali metal salt Chemical class 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 229940083410 myfortic Drugs 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010025280 Lymphocytosis Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000005485 Thrombocytosis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- UJMDYLWCYJJYMO-UHFFFAOYSA-N benzene-1,2,3-tricarboxylic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1C(O)=O UJMDYLWCYJJYMO-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010024378 leukocytosis Diseases 0.000 description 2
- 238000011694 lewis rat Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 208000009786 Anophthalmos Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010411 Congenital central nervous system anomaly Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VIUCZAYKDLEBOL-UHFFFAOYSA-N acetic acid phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O.OC(=O)C1=CC=CC=C1C(O)=O.OC(=O)C1=CC=CC=C1C(O)=O.OC(=O)C1=CC=CC=C1C(O)=O VIUCZAYKDLEBOL-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 231100000364 carcinogenicity testing Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229950010118 cellacefate Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical class CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 125000006203 morpholinoethyl group Chemical group [H]C([H])(*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- KELHQGOVULCJSG-UHFFFAOYSA-N n,n-dimethyl-1-(5-methylfuran-2-yl)ethane-1,2-diamine Chemical compound CN(C)C(CN)C1=CC=C(C)O1 KELHQGOVULCJSG-UHFFFAOYSA-N 0.000 description 1
- 229940063121 neoral Drugs 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 206010045458 umbilical hernia Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
霉酚酸钠 | 180g(以霉酚酸计) |
乳糖 | 40g |
交联PVP | 12.5g |
PVPK30水溶液 | 适量 |
硬脂酸镁 | 1g |
制成 | 1000片 |
欧巴代OY-P型 | 200g |
85%乙醇 | 1000ml |
制成 | 1000ml |
霉酚酸钠 | 180g(以霉酚酸计) |
乳糖 | 40g |
交联PVP | 12.5g |
PVPK30水溶液 | 适量 |
硬脂酸镁 | 1g |
制成 | 1000片 |
醋酸琥珀酸羟丙基甲基纤维素 | 200g |
一氧化钛 | 50g |
80%乙醇 | 2000ml |
制成 | 2000ml |
霉酚酸钠 | 180g(以霉酚酸计) |
乳糖 | 40g |
交联PVP | 12.5g |
PVPK30水溶液 | 适量 |
硬脂酸镁 | 1g |
制成 | 1000片 |
丙烯酸树脂2号 邻苯二甲酸二乙酯 | 250g 100g |
蓖麻油 | 75g |
吐温80 | 35g |
二氧化钛 | 50g |
95%乙醇 | 3000ml |
制成 | 3000ml |
动物 | 口服 | 静脉 |
大鼠 | 700mg/kg | 450mg/kg |
小鼠(mous e) | 2500mg/kg | 550mg/kg |
治疗药物 | 狗编号 | 临床症状和体重变化 |
赋形剂胶囊 | 3 | 正常 |
赋形剂胶囊 | 6 | 正常 |
赋形剂胶囊 | 8 | 正常 |
赋形剂胶囊 | 12 | 正常 |
霉酚酸酯胶囊 | 2 | 第二周偶尔有软便,研究结束时恢复正常 |
霉酚酸酯胶囊 | 4 | 从第一天开始体重下降10%,腹泻4天,食欲 不振1,4-显著活动减退 |
霉酚酸酯胶囊 | 9 | 带血软便,但无临床变化;研究结束时恢复 正常 |
霉酚酸酯胶囊 | 11 | 正常 |
霉酚酸钠 肠溶包衣片 | 1 | 从第一天开始体重下降9%,腹泻3天,食欲 不振,显著活动减退 |
霉酚酸钠 肠溶包衣片 | 5 | 从第一天开始体重下降7%,腹泻3天,显著 活动减退 |
霉酚酸钠 肠溶包衣片 | 7 | 从第一天开始体重下降5%,腹泻5天,食欲 不振,显著活动减退 |
霉酚酸钠 肠溶包衣片 | 10 | 带血迹软便,但没病,研究结束时恢复正常 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100482039A CN1985994B (zh) | 2005-12-19 | 2005-12-19 | 改进的包含霉酚酸盐的包有肠溶衣的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100482039A CN1985994B (zh) | 2005-12-19 | 2005-12-19 | 改进的包含霉酚酸盐的包有肠溶衣的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1985994A CN1985994A (zh) | 2007-06-27 |
CN1985994B true CN1985994B (zh) | 2011-01-12 |
Family
ID=38183023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005100482039A Expired - Fee Related CN1985994B (zh) | 2005-12-19 | 2005-12-19 | 改进的包含霉酚酸盐的包有肠溶衣的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1985994B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1215991A (zh) * | 1996-04-12 | 1999-05-05 | 诺瓦提斯公司 | 霉酚酸盐的包有肠溶衣的药物组合物 |
CN1994295A (zh) * | 2006-01-06 | 2007-07-11 | 华北制药集团新药研究开发有限责任公司 | 霉酚酸盐的包有肠溶衣的药物组合物 |
WO2009022355A1 (en) * | 2007-08-13 | 2009-02-19 | Panacea Biotec Limited | Extended release compositions comprising mycophenolate sodium and processes thereof |
-
2005
- 2005-12-19 CN CN2005100482039A patent/CN1985994B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1215991A (zh) * | 1996-04-12 | 1999-05-05 | 诺瓦提斯公司 | 霉酚酸盐的包有肠溶衣的药物组合物 |
CN1994295A (zh) * | 2006-01-06 | 2007-07-11 | 华北制药集团新药研究开发有限责任公司 | 霉酚酸盐的包有肠溶衣的药物组合物 |
WO2009022355A1 (en) * | 2007-08-13 | 2009-02-19 | Panacea Biotec Limited | Extended release compositions comprising mycophenolate sodium and processes thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1985994A (zh) | 2007-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2615397C2 (ru) | Фармацевтические композиции на основе соли микофеноловой кислоты с энтеросолюбильным покрытием | |
JP3140021B2 (ja) | Tnf阻害剤含有医薬組成物 | |
CN101010070A (zh) | 药物组合物 | |
HU231114B1 (hu) | Mikofenolsavat vagy mikofenolátot tartalmazó gyógyszerkészítmények | |
CN111918646B (zh) | 延迟释放去铁酮片剂及其使用方法 | |
JP2023502067A (ja) | 癌治療のためのbtk阻害剤及びmdm2阻害剤の組合せ | |
WO1994005299A1 (en) | Medicinal composition | |
JPS6343366B2 (zh) | ||
US3934036A (en) | N-benzenesulfonyl-β-alanine hydrazide useful as an immunosuppressive agent | |
CN1985994B (zh) | 改进的包含霉酚酸盐的包有肠溶衣的药物组合物 | |
JP3455633B2 (ja) | 潰瘍性大腸炎の予防又は治療剤 | |
US20020037899A1 (en) | Compositions containing an inhibitor of dihydrofolate reductase and a folate | |
HU190597B (en) | Process for preparing synrtgetic pharmaceutical compositions | |
CN104434850B (zh) | 一种含有阿德福韦酯的口服固体药物组合物 | |
US20050171119A1 (en) | Pharmaceutical formulations with modified release | |
US20220273668A1 (en) | Irak4 degraders and uses thereof | |
JP2015229665A (ja) | メクリジン含有医薬組成物 | |
CA2250906C (en) | Enteric-coated pharmaceutical compositions of mycophenolate | |
JP2621382B2 (ja) | 尿酸排泄剤 | |
KR20000005360A (ko) | 미코페놀레이트의 장용성 약제 조성물 | |
JPH0753375A (ja) | 肝臓疾患治療剤 | |
JPS59184124A (ja) | 腎不全、糖尿病及び糖尿病性腎症におけるエネルギー代謝改善剤 | |
CN102342947A (zh) | 包含阿德福韦和恩替卡韦的口服固体制剂及其应用 | |
PL189960B1 (pl) | Kombinacje kompozycji farmaceutycznych oraz zastosowania tych kombinacji |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HONG THAI LE (BEIJING) MEDICAL TECHNOLOGY DEVELOPM Free format text: FORMER OWNER: HUAXIN SCI-TECH DEVELOPMENT CO., LTD., SHIJIAZHUANG Effective date: 20100813 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 050091 2ND FLOOR, BUILDING 1, ZHENXIN INDUSTRIAL PARK, NO.399, XINSHI NORTH ROAD, SHIJIAZHUANG CITY, HEBEI PROVINCE TO: 100022 ROOM 2201, BUILDING 6, XIANDAICHENG, NO.88, JIANGUO ROAD, CHAOYANG DISTRICT, BEIJING CITY |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20100813 Address after: 100022, room 6, building 2201, modern city, 88 Jianguo Road, Beijing, Chaoyang District Applicant after: Kangtaile (Beijing) Medicine Technology Development Co., Ltd. Address before: 050091 Hebei province Shijiazhuang City Xinshi North Road, No. 399 New Industrial Park No. 1 building two layer Applicant before: Huaxin Sci-Tech Development Co., Ltd., Shijiazhuang |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN AOHE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: KANGTAILE (BEIJING) MEDICINE TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20150511 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150511 Address after: 100022, B, block SOHO, 1203-1204, Jianguo Road, 88, Beijing, Chaoyang District Patentee after: Hainan Union Pharmaceutical Co., Ltd. Address before: 100022, room 6, building 2201, modern city, 88 Jianguo Road, Beijing, Chaoyang District Patentee before: Kangtaile (Beijing) Medicine Technology Development Co., Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: Hainan Union Pharmaceutical Co., Ltd. Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110112 Termination date: 20171219 |